Cytokine

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Retrieved on: 
Thursday, December 14, 2023
Cytokine, Neoplasm, Survival, PD-1, MBA, Pharmacokinetics, PD, CGEM, MPH, Patient, Safety, Pembrolizumab

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial.
  • “CLN-617 is a first-in-class cytokine therapy uniquely combining human IL-2, IL-12, a collagen binding domain, and a size-enhancing domain in a single molecule designed for intratumoral injection.
  • These unique characteristics are intended to promote retention of the cytokines in the injected tumor and potentially provide enhanced safety and efficacy.
  • We look forward to working with investigators to explore the potential of CLN-617, Cullinan Oncology’s sixth program in clinical development.”

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Retrieved on: 
Monday, December 11, 2023
CRS, Patient, Cytokine, DL 2, Survival, Immune system, Hematopoietic stem cell transplantation, PIN, Plasma, Medical director, DL, Leukemia, Mortality, Principal investigator, MD, Graft-versus-host disease, Society, Haematopoietic system, Clinical trial, Infrared spectroscopy correlation table, Blood, Event, Bone marrow, ASH, Death, Observation, IL-6, Cytogenetics, Webcast, Gamma ray, HSCT, Acute myeloid leukemia, Safety, University, AML, NK, Pharmaceutical industry

Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Key Points: 
  • Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
  • Please use this link to participate in the live call; a listen-only version of the webcast is available here .
  • “Leukemic relapse is the leading cause of death in patients undergoing HSCT and prevention of relapse remains a high unmet need.
  • In this trial, the first three patients were high-risk or relapsed AML patients with complex cytogenetics.

Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Retrieved on: 
Monday, November 27, 2023
Montreal Heart Institute, Cytokine, C-reactive protein, Avenanthramide, Research, Blood, MBA, Lipoxygenase, Inflammation, Pharmacokinetics, Observation, CZO, SAD, Biomarker, Nitric oxide, Patient, Safety, Cardiovascular disease, Research institute, Polyphenol, Chemokine

EDMONTON, Alberta, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries, announced today the initiation of its Phase 1 study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.

Key Points: 
  • This Phase 1-2a study (“AvenActive”) is a double-blind, placebo-controlled, randomized, adaptive, first-in-human study designed to assess safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of avenanthramide.
  • Following the Phase 1 portion, pending successful results, the AvenActive protocol also includes a Phase 2a portion for patients presenting evidence of mild to moderate inflammation.
  • Pending successful results in the Phase 1 and potential Phase 2a study, we believe we will be well-positioned for out-licensing opportunities for later stage development and commercialization.
  • With significant market potential and patient benefit, we believe avenanthramides is poised to be the biggest product for Ceapro,” concluded Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro.

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Retrieved on: 
Monday, November 27, 2023
Patient, Atopic dermatitis, Cytokine, Inflammation, Itch, Therapy, Asthma, NRS, Numerical, Safety, RAPT, Pharmaceutical industry

The Phase 1a portion of the trial was a standard single and multiple dose-escalation study in 72 healthy volunteers.

Key Points: 
  • The Phase 1a portion of the trial was a standard single and multiple dose-escalation study in 72 healthy volunteers.
  • The Phase 1b portion of the trial was a randomized, double-blind, placebo-controlled study examining zelnecirnon as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).
  • “We are pleased to have these exciting data published in the prestigious, peer-reviewed journal Allergy,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.
  • Based on the efficacy and safety data observed in the Phase 1b study, RAPT initiated a dose-ranging Phase 2b study in patients with moderate-to-severe AD and a Phase 2a study in asthma.

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Retrieved on: 
Thursday, December 21, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cytokine, Minoxidil, Alopecia areata, Male, Steroid, JAK, Skin, Patient, Therapy, Female, History, Methotrexate, Pharmaceutical industry

“We are pleased to have completed enrollment of the EQ101 Phase 2 study in alopecia areata,” said Bruce Steel, chief executive officer at Equillium.

Key Points: 
  • “We are pleased to have completed enrollment of the EQ101 Phase 2 study in alopecia areata,” said Bruce Steel, chief executive officer at Equillium.
  • “We have enrolled a total of 36 patients in the study, of which 13, or 36 percent, had very severe alopecia areata.
  • These patients are in need of new treatments that may have an improved safety profile compared to recently approved JAK inhibitors.
  • This development also illustrates the utility and modularity of our multi-cytokine platform in generating novel, first-in-class therapeutic candidates.”

Adimab Announces Successful Resolution of Lawsuit Brought Against LinkedUp Bioscience and Tianti Biotherapeutics

Retrieved on: 
Thursday, December 21, 2023
Professional Services, Health, Legal, Other Science, Science, Pharmaceutical, Biotechnology, Cytokine, CD28, Eurosport 1, Confidentiality, Antibody, Spacecraft, FC, Engineering, Complex, Medicine, HC, Immunoglobulin G, G protein-coupled receptor, CD3, Prejudice, Vaccine

In return for undisclosed consideration to Adimab, Adimab has withdrawn its claims that the LinkedUp parties misappropriated Adimab technology or breached any confidentiality agreement, and the LinkedUp parties shall have the unfettered right to continue using their technology as it exists today.

Key Points: 
  • In return for undisclosed consideration to Adimab, Adimab has withdrawn its claims that the LinkedUp parties misappropriated Adimab technology or breached any confidentiality agreement, and the LinkedUp parties shall have the unfettered right to continue using their technology as it exists today.
  • Similarly, LinkedUp and its related parties have withdrawn their counterclaims, including unfair and deceptive trade practices, intentional interference with business relationships, and infliction of emotional distress.
  • Our partners know that we bring unique technology and expertise to our efforts,” added Philip T. Chase, Chief Executive Officer of Adimab.
  • Bispecifics and T-cell engagers: Adimab has extensive bispecific and multispecific capabilities, including common light chain and fragment-based discovery and engineering.

Multiply Labs and Akron Bio Partner to Automate the Use of cGMP-Compliant Liquid Cytokines in Cell Therapy Manufacturing

Retrieved on: 
Wednesday, December 20, 2023
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Robotics, Health Technology, Technology, Manufacturing, Entrepreneurship, Cytokine, Partnership, Risk, Multimedia, Workflow, Syringe, Doctor of Philosophy, GMP, Multiplication, Rhu, Patient, Corporate development, Corporation, Fine chemical

View the full release here: https://www.businesswire.com/news/home/20231219192070/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231219192070/en/
    Multiply Labs' cell therapy robotics system.
  • (Photo: Business Wire)
    Leveraging Multiply Labs' cell therapy robotic cluster, this partnership will enable Akron’s cytokines, starting with cGMP-compliant rHu Interleukin-2 (IL-2) , to be automated with the use of robotics.
  • Multiply Labs’ robotic systems will incorporate Akron’s liquid IL-2 into its cell therapy manufacturing workflow in an aseptic manner, precisely formulating and dispensing the right amount for any given process.
  • “Our partnership with Multiply Labs will allow us to integrate Akron’s cGMP materials into cell therapy manufacturing workflows - simplifying delivery and reducing risk to patients.”
    Akron and Multiply Labs will partner to integrate Akron’s existing cGMP-compliant cytokines with Multiply Labs’ proprietary adapter system, thereby making these materials compatible with Multiply Labs’ cell therapy robotic clusters.

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Retrieved on: 
Tuesday, December 19, 2023
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Immunotherapy, Cytokine, Neoplasm, Tumor microenvironment, Multimedia, IND, Compugen, Science, Cancer, IPR, Patient, Gilead Sciences, EPS, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20231218814564/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231218814564/en/
    Compugen utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies.
  • Gilead will make Compugen an upfront payment of $60 million and $30 million in a near term milestone payment subject to IND clearance of COM503 expected in 2024.
  • Compugen will also be eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales.
  • This transaction with Compugen is expected to reduce Gilead’s GAAP and non-GAAP 2023 EPS by approximately $0.03 - $0.05.

BIO-TECHNE TO PRESENT AT THE 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Retrieved on: 
Thursday, December 21, 2023
Conference, Cytokine, Drug discovery, Gene editing, Antibody, Research, Workflow, FDA, ELISA, ACD, Prostate cancer, ISH, Diagnosis, PST, Calendar, Nature

MINNEAPOLIS, Dec. 21, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, current Chief Operating Officer, and Chief Executive Officer effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST.

Key Points: 
  • MINNEAPOLIS, Dec. 21, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, current Chief Operating Officer, and Chief Executive Officer effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST.
  • A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar .
  • These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.
  • With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide.

BIO-TECHNE ANNOUNCES SUBMISSION OF FDA DRUG MASTER FILE FOR EXCELLERATE GMP IPSC EXPANSION MEDIUM SUPPORTING STEM CELL THERAPY

Retrieved on: 
Wednesday, December 20, 2023
Documentation, Cytokine, Food, IND, Research, FDA, Regenerative medicine, IPSC, DMF, Investigational New Drug, GMP, Therapy, Pharmaceutical industry

ExCellerate GMP iPSC Expansion Medium is optimized to support robust expansion and maintenance of stem cell culture for enhanced consistency and reproducibility throughout the stem cell manufacturing process.

Key Points: 
  • ExCellerate GMP iPSC Expansion Medium is optimized to support robust expansion and maintenance of stem cell culture for enhanced consistency and reproducibility throughout the stem cell manufacturing process.
  • The recently released GMP medium complements Bio-Techne's industry leading regenerative medicine therapy workflow solutions, which includes the widest range of GMP cytokines and growth factors available on the market.
  • The DMF submission provides the FDA with detailed information about the facilities and processes used in the manufacturing, processing, packaging, and storing of ExCellerate GMP iPSC Expansion Medium.
  • Regenerative medicine and stem cell therapy developers who integrate the medium into their GMP cell manufacturing workflows can easily reference these important details when filing Investigational New Drug (IND) applications with the FDA.